Vitamin D Deficiency Promotes Liver Tumor Growth in Transforming Growth Factor-β/Smad3-Deficient Mice Through Wnt and Toll-like Receptor 7 Pathway Modulation

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Chen, Jian ^a   Katz, Lior H ^a,b   Muñoz, Nina M ^a   Gu, Shoujun ^c   Shin, Ji Hyun ^a   Jogunoori, Wilma S ^d   Lee, Mi Hye ^e   Belkin, Mitchell D ^d   Kim, Sang Bae ^a   White, Jon C ^d   Andricovich, Jaclyn ^c   Tzatsos, Alexandros ^c   Li, Shulin ^a   Kim, Sang Soo ^f   Shetty, Kirti ^g   Mishra, Bibhuti ^d   Rashid, Asif ^a   Lee, Ju Seog ^a   Mishra, Lopa ^a,c,h  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b SHEBA MEDICAL CENTER   (Israel)

^c GEORGE WASHINGTON UNIVERSITY   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f National Cancer Center   (South Korea)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MEMBRANE PROTEIN; SMAD3 PROTEIN; SMAD3 PROTEIN, MOUSE; TLR7 PROTEIN, MOUSE; TOLL LIKE RECEPTOR 7; TRANSFORMING GROWTH FACTOR BETA; VITAMIN D; WNT PROTEIN;

ANIMAL; COMPLICATION; EXPERIMENTAL LIVER NEOPLASM; GENETICS; HUMAN; MALE; METABOLISM; MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; VITAMIN D DEFICIENCY;

ANIMALS; HUMANS; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, TRANSGENIC; SIGNAL TRANSDUCTION; SMAD3 PROTEIN; TOLL-LIKE RECEPTOR 7; TRANSFORMING GROWTH FACTOR BETA; VITAMIN D; VITAMIN D DEFICIENCY; WNT PROTEINS;

EID: 84979498158     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep30217     Document Type: Article

References (39)

1. Deeb, K. K., Trump, D. L. & Johnson, C. S. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer 7, 684-700, doi: 10.1038/nrc2196 (2007).
2. Leask, A., Holmes, A., Black, C. M. & Abraham, D. J. Connective tissue growth factor gene regulation. Requirements for its induction by transforming growth factor-beta 2 in fibroblasts. J Biol Chem 278, 13008-13015, doi: 10.1074/jbc.M210366200 (2003).
3. Sato, M. et al. Modulation of transforming growth factor-beta (TGF-beta) signaling by endogenous sphingolipid mediators. J Biol Chem 278, 9276-9282, doi: 10.1074/jbc.M211529200 (2003).
4. Feldman, D., Krishnan, A. V., Swami, S., Giovannucci, E. & Feldman, B. J. The role of vitamin D in reducing cancer risk and progression. Nat Rev Cancer 14, 342-357, doi: 10.1038/nrc3691 (2014).
5. Krishnan, A. V. & Feldman, D. Mechanisms of the anti-cancer and anti-inflammatory actions of vitamin D. Annu Rev Pharmacol Toxicol 51, 311-336, doi: 10.1146/annurev-pharmtox-010510-100611 (2011).
6. Giovannucci, E. Vitamin D status and cancer incidence and mortality. Adv Exp Med Biol 624, 31-42, doi: 10.1007/978-0-387-77574-6-3 (2008).
7. Colombo, M. et al. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 325, 675-680, doi: 10.1056/ NEJM199109053251002 (1991).
8. Arteh, J., Narra, S. & Nair, S. Prevalence of vitamin D deficiency in chronic liver disease. Dig Dis Sci 55, 2624-2628, doi: 10.1007/ s10620-009-1069-9 (2010).
9. George, J. et al. Bone mineral density and disorders of mineral metabolism in chronic liver disease. World J Gastroenterol 15, 3516-3522 (2009).
10. Ding, N. et al. A vitamin D receptor/SMAD genomic circuit gates hepatic fibrotic response. Cell 153, 601-613, doi: 10.1016/j. cell.2013.03.028 (2013).
11. Artaza, J. N. & Norris, K. C. Vitamin D reduces the expression of collagen and key profibrotic factors by inducing an antifibrotic phenotype in mesenchymal multipotent cells. J Endocrinol 200, 207-221, doi: 10.1677/JOE-08-0241 (2009).
12. Ingraham, B. A., Bragdon, B. & Nohe, A. Molecular basis of the potential of vitamin D to prevent cancer. Curr Med Res Opin 24, 139-149, doi: 10.1185/030079908X253519 (2008).
13. Towsend, K. et al. Identification of VDR-responsive gene signatures in breast cancer cells. Oncology 71, 111-123, doi: 10.1159/000100989 (2006).
14. Kitisin, K. et al. Disruption of transforming growth factor-beta signaling through beta-spectrin ELF leads to hepatocellular cancer through cyclin D1 activation. Oncogene 26, 7103-7110, doi: 10.1038/sj.onc.1210513 (2007).
15. Massague, J. TGFbeta in Cancer. Cell 134, 215-230, doi: 10.1016/j.cell.2008.07.001 (2008).
16. Katz, L. H. et al. Targeting TGF-beta signaling in cancer. Expert Opin Ther Targets 17, 743-760, doi: 10.1517/14728222.2013.782287 (2013).
17. Tang, Y. et al. Disruption of transforming growth factor-beta signaling in ELF beta-spectrin-deficient mice. Science 299, 574-577, doi: 10.1126/science.1075994 (2003).
18. Lim, L. Y. & Chalasani, N. Vitamin d deficiency in patients with chronic liver disease and cirrhosis. Curr Gastroenterol Rep 14, 67-73, doi: 10.1007/s11894-011-0231-7 (2012).
19. Paik, Y. H. et al. Toll-like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells. Hepatology 37, 1043-1055, doi: 10.1053/jhep.2003.50182 (2003).
20. Mohamed, F. E. et al. Effect of toll-like receptor 7 and 9 targeted therapy to prevent the development of hepatocellular carcinoma. Liver Int 35, 1063-1076, doi: 10.1111/liv.12626 (2015).
21. Yu, L. X. et al. Endotoxin accumulation prevents carcinogen-induced apoptosis and promotes liver tumorigenesis in rodents. Hepatology 52, 1322-1333, doi: 10.1002/hep.23845 (2010).
22. Sato, K. et al. Expression of Toll-like receptors in chronic hepatitis C virus infection. J Gastroenterol Hepatol 22, 1627-1632, doi: 10.1111/j.1440-1746.2006.04783.x (2007).
23. Murillo, G., Nagpal, V., Tiwari, N., Benya, R. V. & Mehta, R. G. Actions of vitamin D are mediated by the TLR4 pathway in inflammation-induced colon cancer. J Steroid Biochem Mol Biol 121, 403-407, doi: 10.1016/j.jsbmb.2010.03.009 (2010).
24. Zawel, L. et al. Human Smad3 and Smad4 are sequence-specific transcription activators. Mol Cell 1, 611-617 (1998).
25. Revelli, A., Massobrio, M. & Tesarik, J. Nongenomic effects of 1alpha,25-dihydroxyvitamin D(3). Trends Endocrinol Metab 9, 419-427 (1998).
26. Pendas-Franco, N., Aguilera, O., Pereira, F., Gonzalez-Sancho, J. M. & Munoz, A. Vitamin D and Wnt/beta-catenin pathway in colon cancer: role and regulation of DICKKOPF genes. Anticancer Res 28, 2613-2623 (2008).
27. Mishra, B. et al. Loss of cooperative function of transforming growth factor-beta signaling proteins, smad3 with embryonic liver fodrin, a beta-spectrin, in primary biliary cirrhosis. Liver Int 24, 637-645, doi: 10.1111/j.1478-3231.2004.0958.x (2004).
28. Yang, X. et al. Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGFbeta. EMBO J 18, 1280-1291, doi: 10.1093/emboj/18.5.1280 (1999).
29. Kawaratani, H. et al. The effect of inflammatory cytokines in alcoholic liver disease. Mediators Inflamm, 495156, doi: 10.1155/2013/495156 (2013).
30. Zhu, Y., Mahon, B. D., Froicu, M. & Cantorna, M. T. Calcium and 1 alpha,25-dihydroxyvitamin D3 target the TNF-alpha pathway to suppress experimental inflammatory bowel disease. Eur J Immunol 35, 217-224, doi: 10.1002/eji.200425491 (2005).
31. Kwon, H. J. et al. Vitamin D3 upregulated protein 1 suppresses TNF-alpha-induced NF-kappaB activation in hepatocarcinogenesis. J Immunol 185, 3980-3989, doi: 10.4049/jimmunol.1000990 (2010).
32. Tse, A. K. et al. 1alpha,25-Dihydroxyvitamin D3 inhibits transcriptional potential of nuclear factor kappa B in breast cancer cells. Mol Immunol 47, 1728-1738, doi: 10.1016/j.molimm.2010.03.004 (2010).
33. Peleg, S. et al. 1,25-Dihydroxyvitamin D3 and its analogues inhibit acute myelogenous leukemia progenitor proliferation by suppressing interleukin-1beta production. J Clin Invest 100, 1716-1724, doi: 10.1172/JCI119696 (1997).
34. Wang, J. B. et al. Association between serum 25(OH) vitamin D, incident liver cancer and chronic liver disease mortality in the Linxian Nutrition Intervention Trials: a nested case-control study. Br J Cancer 109, 1997-2004, doi: 10.1038/bjc.2013.546 (2013).
35. Fedirko, V. et al. Prediagnostic circulating vitamin D levels and risk of hepatocellular carcinoma in European populations: a nested case-control study. Hepatology 60, 1222-1230, doi: 10.1002/hep.27079 (2014).
36. Ito, I. et al. A nonclassical vitamin D receptor pathway suppresses renal fibrosis. J Clin Invest 123, 4579-4594, doi: 10.1172/JCI67804 (2013).
37. Jakowlew, S. B. Transforming growth factor-beta in cancer and metastasis. Cancer Metastasis Rev 25, 435-457, doi: 10.1007/s10555-006-9006-2 (2006).
38. Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6, pl1, doi: 10.1126/ scisignal.2004088 (2013).
39. Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2, 401-404, doi: 10.1158/2159-8290.CD-12-0095 (2012).